Traditional clinical trials are the gold standard for determining whether a new medicine is safe and effective for its intended use. But some companies, as well as the Food and Drug Administration, are increasingly focused on the question of whether “real-world evidence” can change the way medical researchers study patients — and perhaps even replace control groups in some cases. Join STAT’s senior medicine writer, Matthew Herper, for a subscriber-only live chat on how some experts hope to use real-world evidence and why others are deeply skeptical.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy